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Abstract
Background: Trigeminal neuralgia (TN) is a rare condition for which there are mul-
tiple treatment options available. To date, there has been difficulty in comparing 
the outcomes of treatment due to the variety of patient- reported outcome measures 
(PROMs) and their inadequate psychometric testing. The aim of this review was to 
assess the psychometric properties of PROMs used to date in TN and make recom-
mendations for their use in future studies.
Methods: Five electronic databases (MEDLINE, EMBASE, CINAHL Plus, 
PsycINFO, Health and Psychosocial Instruments) were searched for studies assess-
ing the development of PROMs or their psychometric properties in TN studies. The 
records obtained were assessed independently by two reviewers for their methodo-
logical quality, following guidance from the Consensus- based Standards for the se-
lection of Health Measurement Instruments (COSMIN).
Results: Six studies were identified and information on five PROMs (Brief Pain 
Inventory Facial (BPI- F), Visual Analogue Scale (VAS), Barrow Neurology Institute 
Pain Scale (BNI- PS), Penn Facial Pain Scale- Revised (Penn- FPS- R) and Trigeminal 
Neuralgia Quality of Life Score) were retrieved. The Penn- FPS- R demonstrated 
moderate quality evidence for sufficient content validity. The BPI- F showed moder-
ate evidence for sufficient internal consistency and structural validity but low evi-
dence for inconsistent content validity. The Trigeminal Neuralgia Quality of Life 
score showed very low- quality evidence for insufficient content validity, structure 
validity and responsiveness. No evidence was found on the assessment of any psy-
chometric properties of the VAS and BNI- PS in TN.
Conclusion: There is limited evidence of the psychometric performance of patient- 
reported outcomes for TN and recommendations for their inclusion in future studies 
cannot be made. The validation of PROMs in TN studies should be a priority in this 
field of research.
Significance: This review highlights the knowledge gap in the field of psychomet-
rics of patient reported outcomes measures in the field of TN. Given the unavail-
ability of an objective outcome measure for pain or health related quality of life, 
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1 |  INTRODUCTION
Trigeminal neuralgia (TN) is defined by the International 
Classification of Headache disorders (Olesen,  2018) 
and by the International Classification of Orofacial Pain 
(ICOP, 2020) as ‘A disorder characterized by recurrent uni-
lateral brief electric shock- like pain, abrupt in onset and ter-
mination, limited to the distribution of one or more divisions 
of the trigeminal nerve and triggered by innocuous stimuli’.
Despite being a rare condition, there are multiple surgical 
and pharmacological options available for its management 
and most of the outcomes of treatment collected in different 
studies have used measures that have not been psychometri-
cally tested (Zakrzewska & Relton, 2016).
Over the past two decades, the biopsychosocial model of 
chronic pain has been widely promoted for the assessment and 
management of chronic pain (Gatchel et al., 2007). This has 
alerted the field to move beyond the exclusive assessment of 
pain intensity to allow incorporation of other domains which 
might be more meaningful to patients, such as the impact of 
pain on quality of life (QOL) (Sullivan & Ballantyne, 2016). 
Similar recommendations were made in the TN field (Cruccu 
et al., 2008) but there are scarce examples where it has hap-
pened (Cheng et  al.,  2017; Kotecha et  al.,  2017; Mousavi 
et al., 2016).
Given the subjectivity of constructs like pain and QOL, 
the direct reporting from the patient is of utmost importance. 
Patient- reported outcome measures (PROMs) are question-
naires or forms completed by the patients about their health 
without interpretation by a clinician or researcher (Weldring 
& Smith, 2013). A patient- reported outcome (PRO) can also 
be a record obtained by direct questioning or interviewing of 
the patient.
Patient- reported outcome measures should be chosen on 
their psychometric performance in the studied population 
to allow for comparison of study results. There have been 
repeated calls that measures of PRO assessment should be 
standardized and validated, exemplified by the Big Data for 
Better Outcomes comprehensive European research pro-
gramme (IMI, 2018).
As a minimum, a questionnaire should be validated to be 
used in the target population for the outcome of interest, on 
a specific context, and should therefore be relevant, com-
prehensive and comprehensible – content validity (Terwee 
et  al.,  2018). The instruments should also demonstrate ad-
equate structural validity (the instrument scores reflect the 
construct to be measured), reliability (the scores of the instru-
ment do not change when patients are stable, despite possible 
changes in the timing of the measurement and the instrument 
rater) and responsiveness (if there is a change in the construct 
of interest, for example, due to a new treatment, the instru-
ment is able to detect it). Additionally, the questionnaires 
should also be easy to interpret and be feasible to use without 
causing excessive burden on patients or clinicians (Prinsen 
et al., 2018).
Due to the current lack of guidance on the most appro-
priate instruments to be used in TN studies, the aim of this 
systematic review was to summarize and evaluate the psycho-
metric properties of outcome measures that have been devel-
oped or adapted for TN patients undergoing treatment and to 
make recommendations for their use in future studies.
2 |  METHODS
The methodology adopted for this systematic review fol-
lows guidance from COSMIN (Prinsen et al., 2018) and the 
Preferred Reporting Items for Systematic reviews and Meta- 
Analyses (PRISMA statement) (Moher et al., 2009).
A protocol was prepared and registered in PROSPERO 
(CRD42020185914, 1 July 2020) before starting the system-
atic review process.
2.1 | Literature search
A systematic search was performed in MEDLINE (PubMed) 
(1966– 2020), EMBASE (Ovid) (1980– 2020), CINAHL Plus 
with Full Text (1937– 2020), PsycINFO (Ovid) and Health 
and Psychosocial Instruments (1985– 2020).
The search was designed to identify all studies where 
there was (a) development, evaluation and/or validation of 
measurement properties of (b) PROMs in (c) adult TN patient 
cohorts. A published and validated search filter designed for 
Medline was used, with a high sensitivity for retrieving results 
on measurement properties studies (Terwee et al., 2009). This 
filter was then adapted for search in EMBASE, CINAHL 
and PsycINFO. The search on the Health and Psychosocial 
Instruments database was limited to the target population, 
that is, TN.
The full search strategy can be found in Appendix S1A.
2.2 | Eligibility criteria
Studies were included with a TN patient cohort >18 years of 
age, which aimed to evaluate and/or validate measurement 
psychometrically sound PROMs are essential for assessing medical and surgical 
treatment outcomes in TN.
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properties of PROM(s), develop a PRO or evaluate the in-
terpretability of a PRO. Only full- text articles reported in 
English were included. Studies that described the use of cli-
nician reported outcomes only were excluded. In addition, 
conference abstracts, editorials and conference proceedings 
were also excluded. A choice was made not to search for 
any specific PROM or specify domains or dimensions of the 
PROM as it was anticipated that the search would not yield 
many results.
2.3 | Study records
The records identified were transferred to EndNote X9.2 
(Clarivate Analytics) and duplicates were removed. CVN 
and JMZ independently screened the records by title and ab-
stract. S RB, RNR and CVN independently screened the re-
cords based on full text. Disagreements were resolved with 
discussion. Once records were identified as eligible to be in-
cluded, data were extracted (see below).
2.4 | Measurement properties
2.4.1 | Data extraction
Data were extracted by one author (CVN) using a preselected 
form based on those recommended by COSMIN (Mokkink 
et al., 2018) on both study details (study design, sample size, 
gender, age, TN classification and type of treatment) and 
PROM description (PROM, construct, mode of administra-
tion and psychometric properties under study). A second au-
thor (RNR) confirmed the data extracted for accuracy. There 
were no disagreements.
The measurement properties under study were labelled 
according to the guidance provided by COSMIN (Prinsen 
et al., 2018). This included evidence of the assessment of the 
following measurement properties: content validity, internal 
structure (structural validity and internal consistency) and 
the remaining properties (test– retest reliability, measurement 
error, criterion validity, construct validity and responsive-
ness). Content validity, which is defined by COSMIN as the 
degree to which the content of a PROM is an adequate reflec-
tion of the construct to be measured, is considered the most 
important measurement property.
The assessment of content validity was based on guid-
ance from a recent Delphi study (Terwee et al., 2018), which 
recommends that well- designed PROM development stud-
ies should be taken into consideration in the assessment of 
content validity. Development studies, which use qualitative 
research methods, allow for direct patient input in different 
stages, such as concept elicitation, item generation, compre-
hensibility and comprehensiveness (Magasi et al., 2012).
2.4.2 | Assessment of the methodological 
quality of the studies
Two reviewers (CVN and RNR) independently assessed the 
included studies to evaluate their methodological quality 
and consensus was reached during an online meeting. The 
methodological assessment was done in three steps as recom-
mended by COSMIN.
In step 1, the methodological quality was assessed using 
the risk of bias checklist (Prinsen et al., 2018). This checklist 
consists of a table which outlines all the measurement prop-
erties as well as the PROM development study characteristics 
against quality standards. There are four possible scores for 
each standard: ‘very good’, ‘adequate’, ‘doubtful’ or ‘inade-
quate’. The overall score for the methodological quality of the 
study was taken by using the ‘the worst score counts’ princi-
ple. Details of this can be found in Appendix S1B.
In step 2, criteria for good measurement properties were 
applied by using the following quality ratings: ‘sufficient’ 
(+), ‘insufficient’ (−) or ‘indeterminate’ (?) (see Table 1). At 
this stage, the results of different studies, if consistent, are 
pooled together for assessment of the overall quality rating of 
each PROM as ‘sufficient’ (+), ‘insufficient’ (−), ‘inconsis-
tent’ (±) or ‘indeterminate’ (?).
Finally, in step 3, the Grading of Recommendations 
Assessment, Development and Evaluation modified method 
was used to grade the overall quality of the evidence collected 
of each measurement property as ‘high’, ‘moderate’, ‘low’ or 
‘very low’ (Prinsen et al., 2018; Terwee et al., 2018).
3 |  RESULTS
The search identified 549 titles. After 141 duplicates were 
removed, 408 abstracts were screened. Of these, 18 full- text 
articles were screened but only six were included for the final 
analysis. Figure 1 displays the flowchart of the study records, 
with documented reasons for exclusion in different phases of 
the screening process.
A total of five PROMs were identified in the six articles: 
BPI- F – Brief Pain Inventory Facial (Lee et al., 2010; Sandhu 
et  al.,  2015), VAS – Visual Analogue Scale (Reddy et  al., 
2013, 2014), BNI- PS – Barrow Neurology Institute Pain 
Scale (Reddy et al., 2013, 2014), Penn- FPS- R – Penn Facial 
Pain Scale- Revised (Symonds et al., 2018) and the Trigeminal 
Neuralgia QOL Score (TN QOLS; Luo et  al.,  2019). See 
Table 2 for the characteristics of the included studies.
3.1 | Brief Pain Inventory Facial
The BPI- Facial (Lee et  al., 2010) was intended to be de-
signed as subscale adaptation of the Brief Pain Inventory 
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(Cleeland & Ryan,  1994) to allow for the inclusion of 
seven extra questions specific to interference of pain re-
lated to the face. It included, for example, questions about 
interference of pain on eating a meal or on smiling, laugh-
ing or talking. The BPI was originally developed to be used 
in cancer pain as a pain intensity (severity) and pain inter-
ference tool (Cleeland & Ryan, 1994). Since its develop-
ment, it has been widely used in different pain conditions, 
translated into different languages and validated to be used 
in different clinical and research contexts. The pain inten-
sity subscale consists of four items rated on an 11- point 
scale (0– 10) with anchors ‘no pain’ and ‘pain as bad as 
you can imagine’. The pain interference subscale consists 
of seven items rated on an 11- point scale (0– 10) with an-
chors ‘does not interfere’ and ‘completely interferes’. The 
BPI- F subscale on interference (face) consisted of seven 
T A B L E  1  Criteria for good measurement properties
Measurement property Rating Criteria
Structural validity + CTT
CFA: CFI or TLI or comparable measure >0.95 OR RMSEA <0.06 OR SRMR <0.08
IRT/Rasch
No violation of unidimensionality: CFI or TLI or comparable measure >0.95 OR RMSEA <0.06 OR 
SRMR <0.08
AND
No violation of local independence: residual correlations among the items after controlling for the 
dominant factor <0.20 OR Q3’s <0.37
AND




Rasch: infit and outfit mean squares ≥0.5 and ≤1.5 OR Z- standardized values >−2 and <2
? CTT: not all information for ‘+’ reported
IRT/Rasch: model fit not reported
− Criteria for ‘+’ not met
Internal consistency + At least low evidence for sufficient structural validity AND Cronbach's α(s) ≥0.70 for each 
unidimensional scale or subscale
? Criteria for “At least low evidence for sufficient structural validity” not met
− At least low evidence for sufficient structural validity AND Cronbach's α(s) <0.70 for each 
unidimensional scale or subscale
Reliability + ICC or weighted κ ≥0.70
? ICC or weighted Kappa not reported
− ICC or weighted κ <0.70
Measurement error + SDC or LoA < MIC
? MIC not defined
− SDC or LoA >MIC
Criterion validity + Correlation with gold standard ≥0.70 OR AUC ≥0.70
? Not all information for ‘+’ reported
− Correlation with gold standard <0.70 OR AUC <0.70
Responsiveness + The result is in accordance with the hypothesis OR AUC ≥0.70
? No hypothesis defined (by the review team)
− The result is not in accordance with the hypothesis OR AUC <0.70
Note: “+”, positive rating; “−“, negative rating; ”?”, indeterminate rating.
Adapted from: COSMIN guideline for systematic reviews of patient- reported outcome measures (Prinsen et al., 2018).
Abbreviations: AUC, area under the curve; CFA, confirmatory factor analysis; CFI, comparative fit index; CTT, classical test theory; ICC, intraclass correlation 
coefficient; IRT, item response theory; LoA, limits of agreement; MIC, minimal important change; RMSEA, root mean square error of approximation; SDC, small 
detectable change; SRMR, standardized root mean residuals; TLI, Tucker– Lewis index.
F I G U R E  1  Flowchart of search strategy results
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T A B L E  2  Characteristics of included studies












Cross sectional Based on the International 
Headache Society 
Classification (2nd edition) 
and Burchiel Type 1 classic 
TN or Burchiel Type 2
156 (63%) Type 1 – 61 (SD 
not available)
Type 2 – 56 (SD 
not available)
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60 (78%) 53.4 ± 12.3 MVD VAS
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Pain intensity Face to face 
interviews at 
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available)
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thermocoagulation










Abbreviations: BNI- PS, Barrow Neurological Institute Pain Scale; BPI- F, Brief Pain Inventory Facial; MVD, microvascular decompression; PROM, patient reported  
outcome measure; SD, standard deviation; TN QOLS, Trigeminal Neuralgia Quality of Life Score; VAS, Visual Analogue Scale.
aSubscale development and interpretability are not considered measurement properties but the former can be used to aid in content validity assessment and the latter  
should be assessed when the other measurement properties fulfil criteria of quality.
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new items rated on an 11- point scale (0– 10) with anchors 
‘does not interfere’ and ‘completely interferes’.
One study presented data on the BPI- F subscale devel-
opment, structural validity and internal consistency (Lee 
et al., 2010), and one study presented data on the scale's in-
terpretability (Sandhu et al., 2015).
3.1.1 | Validity
Subscale development and content validity
The subscale development study (Lee et  al.,  2010) was of 
doubtful quality as it is unclear if patients were asked about 
the comprehensibility and comprehensiveness of the PROM.
In the absence of content validity studies for this subscale, 
the content validity rating was based on the development 
study and on the reviewer's ratings which provided low ev-
idence for inconsistent findings.
3.1.2 | Internal structure
Structural validity and internal consistency
One study of adequate quality assessed the structural va-
lidity and internal consistency of the BPI- Facial (Lee 
et al., 2010); however, it was not clear if the items of the 
subscale were based on a reflective or formative model 
but it was assumed that the items of the ‘pain interference 
facial’ construct were based on a reflective model drawn 
from the literature and consultation of experts in the field. 
The authors of the study hypothesized that the BPI- Facial 
could be a two- or three- factor questionnaire and conducted 
a principal factor analysis with varimax rotated factor. 
Three factors with eigenvalues >1 (interference facial 5.4/
interference general 4.3/pain intensity 2.3) were identified 
and confirmed with a scree plot. The three factors explained 
97.6% of the variance of the instrument. A cut- off >0.4 was 
used for the loading values suggesting a high correlation 
of the items with the domain. The pain interference facial 
factor loading varied from 0.73 (impact of pain on eating) 
to 0.87 (impact of pain on brushing and on smiling). These 
findings suggest moderate evidence for sufficient unidi-
mensionality of the pain interference subscale.
The internal consistency of the pain interference fa-
cial  subscale was 0.95 calculated using Cronbach's α. 
Taking into consideration the moderate evidence for 
 sufficient structural validity and Cronbach's α >0.70, 
there  is moderate evidence for sufficient internal 
consistency.
Interpretability
According to COSMIN, interpretability is not a measurement 
property, rather a feature to be taken into consideration when 
choosing an instrument as it attributes meaning to an instru-
ment's single score or change in scores (Prinsen et al., 2018). 
One study assessed the interpretability of the BPI- Facial by 
calculating the minimum clinically important difference with 
two anchor- based methods: mean change score and receiver 
operating curve analysis (Sandhu et al., 2015). The patient 
global impression of change scale (PGIC) was the anchor 
used which patients completed on follow- up choosing one 
of the following options: very much improved, much im-
proved, minimally improved, no change, minimally worse, 
much worse and very much worse. The mean change score 
was calculated for one subgroup only (‘much improved’ 
n  =  47) and percentages of change in scores calculated. 
Patients needed a 30% and 44% improvement in pain inten-
sity worst and average, respectively, to choose the ‘much 
improved option’ and a higher percentage change of scores 
for interference general (54%) and interference facial (63%). 
Cut- off points were calculated for the domains pain intensity 
(worse and average), interference general and interference 
facial for three different models based on the distribution of 
patients on the PGIC scale – very much improved, much and 
very much improved, minimally and much and very much 
improved. The model chosen for analysis was the one which 
included much and very much improved patients (n = 159). 
Sensitivity and specificity were calculated. For worst and 
average pain intensity and interference general, sensitivity 
was 65.5%, 65.7% and 68.3%, respectively, which indicates 
that there is a moderate percentage of false positive misclas-
sifications. Specificity was higher for all the domains rang-
ing from 71.9% (interference facial) to 90.7% (worst pain 
intensity).
3.2 | Barrow Neurology Institute Pain Scale
The BNI- PS was used for the first time in a study designed to 
assess the efficacy of gamma knife radiosurgery in a cohort of 
TN patients and, according to the authors, it is a pain intensity 
scale (Rogers et al., 2000); however, requirement for medica-
tion is also taken into account. The scoring options outlined on 
that initial study are: ‘I – No trigeminal pain, no medication’, 
‘II – Occasional pain, not requiring medication’, ‘III – Some 
pain, adequately controlled with medications’, ‘IV – Some 
pain, not adequately controlled with medication’ and ‘V – 
Severe pain/no relief’. For a more comprehensive description 
of this questionnaire, see the review by Sandhu & Lee (2016).
To the best of our knowledge, there is no evidence in the 
literature of any studies that attest or attempt to validate the 
BNI- PS for its use in TN studies. The author of the study, 
where it was used for the first time, was contacted by email 
for clarification, but we have not obtained a reply. It is not 
clear if patients complete it or if the data are taken from med-
ical records.
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3.2.1 | Interpretability
Two of the included studies were designed to determine the 
interpretability of the BNI- PS (Reddy et al., 2013, 2014) but 
the authors of this review agreed that the interpretability of 
the questionnaire has no significance without evidence of its 
measurement properties.
3.3 | Visual Analogue Scale
Two of the included studies were designed to determine the 
interpretability of the VAS (Reddy et al., 2013, 2014). The 
VAS is a pain intensity scale widely used (Price et al., 1997). 
It is an unidimensional continuous scale which scores pain 
intensity on a 10- cm (100  mm) horizontal or vertical line 
(Kahl & Cleland,  2005). There have been some criticisms 
of the feasibility of using VAS as a pain intensity measure-
ment, related with the difficulties that the elderly or those 
with cognitive and physical impairment have in completing 
it which might result in missing data. For this reason, the 
Initiative on Methods, Measurement and Pain Assessment in 
Clinical Trials recommends the numerical rating scale for the 
assessment of pain intensity in clinical trials of chronic pain 
(Dworkin et al., 2005).
3.3.1 | Interpretability
The studies which aimed to determine the interpretabil-
ity of the BNI- PS also set to determine the interpretabil-
ity of the VAS. Given the absence of VAS psychometric 
studies within the TN literature, we have not described its 
interpretability.
3.4 | Penn Facial Pain Scale- Revised
The Penn- FPS- R was developed with the intent to be a re-
vised version of the Penn Facial Pain Scale which was in 
turn previously called the BPI- Facial (see description above), 
due to the absence of content validity properties (Symonds 
et al., 2018). Similar to the BPI- Facial and to the Penn Facial 
Pain scale, the Penn- FPS- R was designed to capture details 
on general and TN- specific pain interference. The original 
BPI- Facial and the Penn Facial Pain Scale included items re-
lated to pain interference on activities of daily living specific 
to patients living with TN such as ‘eating a meal’, ‘touch-
ing one's face’, ‘brushing or flossing one's teeth’, ‘smiling 
or laughing’, ‘talking’, ‘opening one's mouth widely’ and 
‘eating hard food like apples’ (Symonds et al., 2018). These 
seven items were rated on an 11- point scale (0– 10) with an-
chors ‘does not interfere’ and ‘completely interferes’. In a 
qualitative study with TN patients (Symonds et  al.,  2018), 
the item ‘eating hard food like apples’ was removed and re-
placed by ‘biting or chewing’ and two new items were added, 
‘self- care’ and ‘activities affected by temperature changes’. 
Furthermore, the original BPI- Facial included seven items of 
general pain interference such as impact of pain on ‘walk-
ing ability’, ‘normal work’, ‘sleep’ and ‘enjoyment of life’, 
which the participants of this study decided were not relevant 
in the context of their disease. The finalized version of Penn- 
FPS- R is a questionnaire which includes 12 items (Symonds 
et al., 2018).
3.4.1 | Validity
Subscale development and content validity
The subscale development study was of adequate quality 
(Symonds et  al.,  2018). In the absence of content validity 
studies with new patient cohorts, the content validity rating 
was based on the development study and on the reviewer's 
ratings which provided moderate quality evidence for suffi-
cient content validity.
3.5 | Trigeminal Neuralgia Quality of 
Life Score
We have identified one study which aimed to develop a TN- 
specific QOL subscale for the Quality of Life Instruments 
for Chronic Diseases (QLICD), which is a questionnaire de-
veloped to assess QOL in Chinese populations with chronic 
diseases (Luo et al., 2019). It consists of a general subscale 
(QLICD- GM) and disease- specific subscales, which exist for 
hypertension, irritable bowel syndrome and chronic obstruc-
tive pulmonary disease, to name a few (Wan et  al.,  2011). 
Despite the use of qualitative methods in the development of 
the QLICD- GM, patients were not involved nor were they 
asked about the contents of the questionnaire; therefore, it 
cannot be assumed that this general subscale has content 
validity.
3.5.1 | Validity
Subscale development and content validity
One study aimed to develop and confirm content valid-
ity for the TN- specific QOL subscale of the QLICD (Luo 
et al., 2019). The questionnaire development was of doubt-
ful quality, as we could not retrieve any details on the ex-
tent of patient involvement. Content validity ratings were 
based on the development study and on the reviewer's rat-
ings as there was no indication of the subscale being tested 
on a new cohort. The reviewers deemed content validity 
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insufficient. This resulted in very low quality for insuffi-
cient content validity.
Criterion validity
Criterion validity was described but not assessed in this re-
view, as there are no gold standard questionnaires to assess 
QOL in TN cohorts.
3.5.2 | Internal structure
Structural validity and internal consistency
The authors used factor analysis to determine the structural 
validity of the TN QOLS in a study of doubtful quality. Four 
factors were identified which account for 65.82% of variance. 
Due to the lack of further information on the factor analy-
sis results (e.g. there was no information on the eigenvalues, 
nor was there information on the cut- off value for the factor 
loadings), there is very low evidence for insufficient structure 
validity.
Cronbach's α was calculated for internal consistency, and 
results were >0.70 for each of the four factors; however, due 
very low evidence for insufficient structural validity, internal 
consistency was deemed indeterminate.
Responsiveness
It is unclear how responsiveness was determined on a study 
of inadequate quality as there was no evidence of hypothesis 
testing with a comparator outcome measure. Responsiveness 
of TN QOLS was insufficient based on very low- quality 
evidence.
4 |  DISCUSSION AND 
CONCLUSION
This systematic review is the first to use COSMIN guidance 
to evaluate the measurement properties of PROMs used in 
patients with TN.
The review identified six studies, in which five different 
PROMs were used to assess pain intensity, pain interference 
on activities (general and facial) and pain interference on 
QOL and daily activities.
A previous systematic review had highlighted the vast 
number of questionnaires being used in TN studies, with 10 
and 9 different questionnaires used for pain relief and pain 
intensity, respectively (Venda Nova et al., 2020). The results 
of the present review demonstrated that very few attempts 
to validate existing questionnaires have been made and that, 
when it has happened the quality of the evidence has been 
suboptimal (Table 3). The lack of comparative studies which 
aim to assess the validity, reproducibility and responsiveness 
of different questionnaires is striking and has contributed to 
uncertainties around the best measurement approaches in the 
TN field.
With the exception of the Penn- FPS- R, which demon-
strated moderate evidence for content validity (Symonds 
et al., 2018), the BPI- Facial demonstrated low evidence for 
inconsistent content validity (Lee et  al.,  2010) and the TN 
QOLS has very low evidence for insufficient content valid-
ity (Luo et al., 2019). Content validity is the most important 
measurement property and involving patients in development 
studies and validation studies is a requirement according to 
current guidance (Terwee et al., 2018). Confirming that the 
T A B L E  3  Evidence synthesis of measurement properties of PROMs used in patients with Trigeminal Neuralgia
Measurement property














Relevance ± Low + Moderate − Very low
Comprehensibility ± Low + Moderate − Very low
Comprehensiveness ± Low + Moderate − Very low
Structural validity + Moderate − Very low





Responsiveness − Very low
Note: Empty cells = measurement properties not assessed. “+”, sufficient; “−“, insufficient; “±”, inconsistent.
Abbreviations: BPI- Facial, Brief Pain Inventory – Facial; Penn FPS- R, Penn Facial Pain Scale Revised; TN QOLS, Trigeminal Neuralgia Quality of Life Score.
aConstruct Validity: rating based on questionnaire development study and reviewers’ ratings.
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questionnaire is relevant, comprehensible and comprehensive 
from the patient perspective and for the context of use is at 
the core of a well- designed patient- reported tool. The ques-
tionnaire should be able to capture the patient's experience 
of living with the disease and how it impacts on their lives 
(Devlin & Appleby, 2010).
Regulatory agencies like the US Food and Drug 
Administration (FDA) and the European Medicines Agency 
(EMA) recommend the inclusion of PROs and outcome 
measures on clinical trials (Gnanasakthy et al., 2019). This 
is particularly relevant for TN as most studies aim primarily 
to assess the effectiveness of treatment on pain reduction. In 
this context, a PRO should be used as a primary outcome/
endpoint, given the inherent subjective nature of pain reports. 
In studies for which no objective primary outcomes exist, the 
benefit of using methodologically sound patient- reported in-
struments is even more critical.
The BNI- PS (Rogers et al., 2000) is without a doubt the 
most replicated outcome measure in surgical studies of TN, 
yet, no evidence could be found in the literature of any stud-
ies which aimed to validate the questionnaire to assess pain 
intensity in TN cohorts. While it is recognized that the guid-
ance available from COSMIN was not available when the 
BNI- PS was first developed, it has been widely available for 
at least a decade. Yet, the BNI- PS continues to be used and 
its scores are perpetually compared between studies to draw 
conclusions on treatment effectiveness. This is probably due 
to its ease of use.
Similar to the BNI- PS, the VAS (Price et al., 1997) has 
been extensively used in TN literature, with no evidence 
available for its content validity as illustrated in the present 
work. A recent systematic review of TN studies found that 
the VAS has been used not only as a pain intensity outcome 
measure, as found in 85 of the 193 (44%) studies assessing 
pain intensity, but, interestingly, in those assessing pain re-
lief, as seen in 18 of the 314 (6%) studies assessing pain relief 
(Venda Nova et al., 2020). It is possible that it is also due to 
its ease of use, although it might not be feasible for all patient 
populations.
The fact that there is a lack of evidence on the content 
validity of the two most widely used questionnaires for pain 
intensity and pain relief should be a concern to the field.
The BPI- Facial (Lee et al., 2010) has demonstrated suf-
ficient structural validity and internal consistency in a study 
of moderate quality, however, as explained above, as it has 
failed to include patients in its design. As such, these posi-
tive results become meaningless in the absence of any evi-
dence to demonstrate content validity. This questionnaire has 
subsequently been replaced by the Penn- FPS- R (Symonds 
et al., 2018).
Responsiveness was inadequately assessed for the TN 
QOLS and no studies assessed it for any other PROMs. 
Responsiveness is defined by COSMIN as ‘the ability of an 
instrument to detect change over time in the construct to be 
measured’ (Terwee et  al.,  2011). When designing clinical 
studies of TN, where the expectation is that the construct 
under study improves to a certain extent, it is then important 
to utilize an instrument able to capture the change in scores 
from baseline to after intervention.
As discussed in the introduction, the importance of 
using validated questionnaires has been thoroughly de-
scribed in the literature (Prinsen et al., 2016) and the ben-
efits of doing so, highlighted. Examples of this are the 
ability to compare study results and draw meaningful con-
clusions through meta- analysis. Another example relates to 
the waste of research resources when studies continue to 
be designed without incorporating psychometrically sound 
questionnaires. There is no doubt that this is essential for 
all diseases, but it becomes even more so for rare condi-
tions such as TN where financial support is scarce and re-
cruitment of patients for trials can be challenging (Slade 
et al., 2018; Zakrzewska et al., 2018). Unusual for the pain 
field, there are both medical and surgical treatments avail-
able for TN with the latter providing more long- term pain 
relief but with increased risk of complications. In such sit-
uations, patients need to be able to compare these when 
making informed decisions about their treatment.
4.1 | Future directions
The results of this systematic review will inform an ongo-
ing study on the development of a Core Outcome Set for TN 
(TRINCOS study). However, at this stage, we are unable to 
make recommendations for the use of any of the question-
naires included in this review, without further psychometric 
studies.
When designing a study to assess the measurement prop-
erties of an instrument, it is important to have in mind the 
construct or domain of interest (Terwee et al., 2018). We are 
currently working with TN patients to clarify what outcome 
domains are important to them. We hypothesize that domains 
other than pain will be of value to patients, for example, 
how much interference does the pain cause to their QOL, 
their daily activities or their mood. Results from a recent 
cross- sectional study on the burden of illness (O’Callaghan 
et  al.,  2020) support this hypothesis; therefore, this infor-
mation should be taken into account in the design of future 
psychometric studies. Additionally, TN patients can present 
with different disease phenotypes, that is, in some, the pain 
might be purely paroxysmal with variable periods of remis-
sion, but others might present with a continuous background 
pain, which persists in between the attacks (ICOP,  2020). 
Outcomes of surgical and pharmacological treatment appear 
to be worse in patients with concomitant pain (Cruccu, 2017; 
Maarbjerg et al., 2014; Zhang et al., 2013). These distinctive 
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characteristics of TN should be taken into account when de-
signing or validating questionnaires.
Researchers considering developing and/or validating 
PROMs could use the results of this review and those of our 
future work with patients to inform their study designs. We 
would recommend, as a priority, that instruments currently 
used in TN are assessed for content validity, and that future 
studies could include a comparative assessment of multiple 
instruments. We would also recommend that further psycho-
metric testing is done with the Penn- FPS- R, such as looking 
at its reliability and responsiveness.
Given the challenge of patient recruitment in TN, research-
ers working in the field might alternatively want to consider 
using questionnaires that have been validated in other chronic 
pain fields and adapt these to be used in cohorts of TN pa-
tients, rather than trying to develop a new questionnaire.
4.2 | Limitations
Despite our efforts to conduct an extensive search in five dif-
ferent databases with a validated search filter, we have not 
looked at grey literature, and we might have left out relevant 
studies, which could have contributed to the evidence, help-
ing to refute or support our findings. The search strategy 
was limited to studies in English and it is, therefore, possi-
ble that good quality psychometric studies published in other 
languages were excluded. These limitations might help to 
explain why we have not been able to make a strong recom-
mendation for the use of any specific questionnaire as we 
have retrieved very few studies and within these, not all of the 
nine recommended measurement properties were assessed.
5 |  CONCLUSION
This systematic review highlighted the gap that exists in the 
TN literature on PROMs and has, therefore, failed to provide 
guidance on which PROMs should be preferred in TN stud-
ies. The Penn- FPS- R has promising content validity results, 
but it needs further investigation of its internal structure and 
responsiveness.
A substantial future research programme is needed to im-
prove the development and evaluation of PROMs in TN.
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